source
- Beam Therapeutics reports year-long reduction in sickle cell crises in phase 1/2 risto-cel studyBeam Therapeutics disclosed data from its phase 1/2 trial of risto-cel, a base-edited autologous cell therapy targeting the BCL11A gene in sickle cell disease. The trial enrolled 31 adults and ado…
- Marea Therapeutics' triglyceride drug lowers levels without raising blood sugar in high-risk patientsMarea Therapeutics reported new data on its investigational lipid‑lowering medicine, showing it can further reduce triglyceride levels in patients with dangerously high blood concentrations. The s…Endpoints · 1d agoPositive readoutPositive